CEACAM5 and colorectal cancer: Accordingly, the development of targeted dual-labeled probes has gained enthusiasm, with several agents targeting adult tumors now in the early stages of development, including 111In-DTPA-labetuzumab-IRDye800 which targets CEA for colorectal cancer, 111In-DTPA-bivatuzumab-IRDye800 which targets CD44 for head and neck cancer, and 111In-DOTA-girentuximab-IRDye800 for renal cell carcinoma [17–19].